The ΗDHC Nuclear Medicine Theranostics Center not only performs the following in vivo, diagnostic tests, but can carry out imaging studies as well:

• Whole-body bone scintigraphy and three-phase bone scintigraphy. 
• Myocardial perfusion scintigraphy (MPS).
• Myocardial scintigraphy with TI-201 for the assessment of myocardial viability.
• Resting multiple gate acquisition (MUGA) scan.
• Thyroid scintigraphy. 
• Parathyroid scintigraphy [(dual-isotope subtraction technique & dual phase technique).
• Scintigraphy for Sentinel Lymph Node detection.
• Brain scintigraphy.

Brain scintigraphy for the diagnosis of Parkinson’s disease (DaTscan).

• Static renal scintigraphy.
• Dynamic renal scintigraphy (renogram). 
• Adrenal gland scintigraphy with MIBG.
• Lung perfusion scintigraphy (LPS). 
• Somatostatin receptor scintigraphy (SRS).
• Scintigraphy for the detection of gastrointestinal bleeding. 
• Whole-body I-131 scintigraphy. 
• Whole-body Ga-67 scintigraphy. 
• Scintigraphic detection of inflammation.

In the context of the continuous upgrading of its biomedical equipment with the acquisition of state-of-the-art technology, ΗDHC has installed a dual-head gamma camera (Siemens Symbia Evo Excel) at the department of Nuclear Medicine, which is the newest and most comprehensive model of its class. Its great advantage is the ability to scan overweight patients as it has a weight limit of 227 Kg, and can perform with high reliability, high resolution and in less time (compared to conventional ones), all scintigraphy, even the most specialized.

Therapeutic application of radioactive isotopes 

The Nuclear Medicine Theranostics Center features two single bed treatment rooms, fully shielded and equipped with a closed circuit through which the specialized nursing and medical staff monitor the patients on a 24-hour basis. They are also equipped with telephone, TV (smart TV) and Internet connection (Wi-Fi). 

Patients requiring Ι-131 therapy for the treatment of malignancies, as well as benign thyroid diseases can be hospitalized in these rooms.

ΗDHC is the first Private Hospital in Greece that has treated patients with castration-resistant prostate cancer using alpha-radiation therapy (Ra-223). Moreover, beta-emitters can also be used for the treatment of painful bone metastases, regardless of the primary tumor. Finally, our department has been licensed to conduct ¹⁷⁷Lu-DOTATATE treatments in patients with neuroendocrine tumors (ΝΕΤ).

The specialized Medical staff of the Therapeutic Nuclear Medicine Department in collaboration with the other highly experienced scientific staff (Medical Physicist, Technicians, Nurses), guarantee to offer optimal treatment to patients.